Patents Examined by Eric S. Olson
  • Methods for transdifferentiation of body tissues
    Patent number: 8575128
    Abstract: The invention relates to methods for transdifferentiation of body tissues which can be used to generate specific cell types needed for regenerating organs or body parts, following cellular degeneration, injury or amputation. The present invention also describes the use of tissue transdifferentiation for treating cancer and autoimmune disease.
    Type: Grant
    Filed: March 6, 2012
    Date of Patent: November 5, 2013
    Inventor: Steven Baranowitz
  • Acid-sensitive linkers for drug delivery
    Patent number: 8575359
    Abstract: The invention is in general directed to acid-sensitive linkers, and methods of use thereof, such as, for example, in drug delivery methods.
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: November 5, 2013
    Assignee: The Regents of the University of California
    Inventors: Jerry Yang, Seong Deok Kong, Alice Luong, Stephen Howell
  • Hydroxyethylstarch
    Patent number: 8569480
    Abstract: Described are a hydroxyethylstarch, a process for the preparation thereof, a pharmaceutical formulation containing such a hydroxyethylstarch, and the use of the pharmaceutical formulation for the preparation of a volume replacement, a plasma replacement or a plasma volume expander, as well as the use of the pharmaceutical formulation for maintaining normovolemia and/or for improving the macro- and microcirculation and/or for improving the nutritive oxygen supply and/or for stabilizing hemodynamics and/or for improving the volume efficiency and/or for reducing the plasma viscosity and/or for increasing anemia tolerance and/or for hemodilution, especially for therapeutic hemodilution in disturbed blood supply and arterial, especially peripheral arterial, occlusive diseases.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: October 29, 2013
    Assignee: B. Braun Melsungen AG
    Inventors: Michael Boll, Andreas Fisch, Donat R. Spahn
  • Triazole derivatives, their preparation and their application in therapeutics
    Patent number: 8563526
    Abstract: The present invention relates to novel compounds of formula (A): in the form of a free base or of an addition salt with an acid. The invention also relates to process of preparation of compounds of formula (A), to composition comprising them and to their application in therapeutics and in particular in cancers.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: October 22, 2013
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (C.N.R.S.)
    Inventors: Ling Peng, Palma Rocchi, Juan Iovanna, Yi Xia, Fanqi Qu, Jinqiao Wan, Yang Liu, Menghua Wang
  • Compounds, compositions and methods for preventing skin darkening
    Patent number: 8563754
    Abstract: A method for preventing hyperpigmented skin, undesired pigmentation disorder of skin, or undesired darkening of skin using coumarin compounds, the use of such compounds, and compositions and formulations thereof are disclosed. In a particular embodiment, the coumarin compounds are selected from robustic acid methyl ether, scandenin, and coumophos. The compounds may be prepared as additives to pharmaceutical and cosmetic compositions, and in personal care products such as antiperspirants. In a particular embodiment extends to an antiperspirant product containing a skin darkening inhibitory amount of a compound of the invention. Also, the present skin darkening compounds may be prepared in combination with each other.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: October 22, 2013
    Assignee: New York University
    Inventors: Seth J. Orlow, Li Ni Komatsu
  • Method of producing polysaccharide derivatives
    Patent number: 8557986
    Abstract: A polysaccharide derivative having a high solubility in an aqueous solvent is produced. The production method of the present invention uses a compound shown by the general formula (1) as a condensing agent and allows a polysaccharide having a carboxyl group to react with an an organic compound having a functional group capable of condensing with the carboxyl group to prepare the polysaccharide derivative: R1 and R2 independently represent a substituent selected among alkyl groups of 1 to 4 carbon atoms and aryl groups of 6 to 8 carbon atoms; Z?represents a counter anion; and E+represents an organic group shown as: R3, R4, and R5 independently represent an organic group having at least one carbon atom directly bound to a quaternary nitrogen atom and any two or all of R3, R4, and R5 may link together to form a cyclic structure.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: October 15, 2013
    Assignee: Seikagaku Corporation
    Inventor: Yousuke Yasuda
  • Galactosylated pro-drugs of non-steroidal anti-inflammatories with improved pharmacokinetic characteristics and reduced toxicity of the starting drug
    Patent number: 8551958
    Abstract: Pro-drugs of all non-steroidal anti-inflammatories with free acid function derivatized with an ester group, which have the general structural formula given below (I) where A is: aspirin, diflunisal, benorylate, ibufenac, diclofenac, indomethacin, sulindac, ketorolac, ibuprofen, naproxen, ketoprofen, fenoprofen, flurbiprofen, mefenamic acid, meclof enamic acid, flufenamic acid, niflumic acid, and where in the ester group R can be a sugar (amongst which aldose, or ketose pentose, or esose selected from a group of D- and L-enantioiuers of ribose, glucose, galactose, mannose, arabinose, xilose, allose, altrose, gulose, idose and talose and substituted derivatives thereof, such as glucosamine, galactosamine, N-acetyl glucosamine, N-acetyl galactosamine, N-acetyl ribosamine), a disaccharide, a trisaccharide or an oligosaccharide.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: October 8, 2013
    Assignees: Stewart Italia Srl
    Inventors: Maria Grazia Rimoli, Antonio Calignano, Rosario Cuomo, Gianpiero Boatto, Enrico Abignente, Daniela Melisi, Annalisa Curcio, Elvira Luongo, Giovanna La Rana, Oscar Sasso, Giovanni Sarnelli, Roberto Russo, Maria Nieddu, Carla Cirillo, Salvatore De Lucia
  • Liver-targeting agents and their synthesis
    Patent number: 8552163
    Abstract: This invention provides novel liver targeting agents and their synthetic methods. A liver targeting agent, with a lysine based nitrilotriacetic acid structure as backbone which acquires multivalency with saccharide groups, to bind with a galactosamine chain or lactose chain is disclosed. In particular, only one amino acid L-lysine is involved to provide trivalency. All carboxyl groups in N?-benzyloxycarbonyl-N?-dicarboxymethyl-L-lysine can be conjugated with three glycosides of ahGalNAc or ahLac in one step. This invention also provides a hexa-lactoside. In particular, the TFA-AHA-Asp was used to conjugate 2 molecules of NTA(ahLac)3. This invention also provides a method for adding a spacer between NTA and DTPA. The extended hepatocyte-specific glyco-ligand has higher 111In-radiolabelling yield than those non-extended.
    Type: Grant
    Filed: September 27, 2010
    Date of Patent: October 8, 2013
    Assignees: Johns Hopkins University, Institute of Nuclear Energy Research Atomic Energy Council, Executive Yuan
    Inventors: Reiko Takasaka Lee, Yuan-Chuan Lee, Mei-Hui Wang, Wuu-Jyh Lin
  • Anti-viral pyrimidine nucleoside analogues
    Patent number: 8551965
    Abstract: A compound of formula (I) wherein Ar can be one six-membered or two fused six-membered aromatic rings; R8 and R9 can be hydrogen, alkyl, cycloalkyl, halogens, amino, alkylamino, dialkylamino, nitro, cyano, alkyoxy, aryloxy, thiol, alkylthiol, arythiol, or aryl; Q can be O, S or CY2, where Y may be H, alkyl or halogens; X can be O, NH, S, N-alkyl, (CHR2)m where m is 1 to 10, and CY2; Z can be O, S, NH, or N-alkyl; U? is H and U? can be H or CH2; wherein: T can be OH, H, halogens, O-alkyl, O-acyl, O-aryl, CN, NH2. or N3; T? and T? can be H or halogen; and W can be H or a phosphate group. Compounds show anti-viral activity, for example with respect to varicella zoster virus.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: October 8, 2013
    Assignees: University College Cardiff Consultants Limited, Rega Foundation
    Inventors: Christopher McGuigan, Jan Balzarini
  • Process for modification of biopolymers
    Patent number: 8552178
    Abstract: A biopolymer thinning process is provided comprising the steps of (a) mixing a biopolymer substrate with a thinning agent and an alkalizing agent; and (b) drying the mixture of step (a), wherein the thinning agent consists of one or more hypochlorites; and step (a) is carried out at a neutral to alkaline pH and does not involve any artificial heating.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: October 8, 2013
    Assignee: Cargill, Incorporated
    Inventors: Marc Charles Florent Berckmans, Dogan Sahin Sivasligil
  • Compounds and combinations
    Patent number: 8546353
    Abstract: The present invention relates to a combination of a hyaluronan oligomer and/or polymer and a factor capable of mobilizing stem cells. The present invention also relates to a method for altering the relative amounts of blood cells and/or the types of blood cells in a subject by administering the combination to the subject. Further, the present invention relates to a method for mobilizing stem cells to the bloodstream of a subject by administering the combination to the subject. Additionally, the present invention relates to a hyaluronan oligomer and/or polymer.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: October 1, 2013
    Assignee: Glykos Finland Oy
    Inventors: Johanna Nystedt, Heidi Anderson, Tero Satomaa, Jari Natunen, Jari Helin, Juhani Saarinen
  • Administration form of osteogenic protein complexes
    Patent number: 8546356
    Abstract: Osteogenic compositions composed of a coprecipitate that contains at least one insoluble calcium salt and at least one complex between an osteogenic protein and a polysaccharide, the coprecipitate being in divided form, are described. Kits are also described, as are a process for preparing the coprecipitate in divided form, containing at least one insoluble calcium salt and at least one complex between an osteogenic protein and a polysaccharide.
    Type: Grant
    Filed: November 19, 2009
    Date of Patent: October 1, 2013
    Assignee: ADOCIA
    Inventors: Olivier Soula, Remi Soula, Gerard Soula
  • 11-aza, 11-thia and 11-oxa sterol compounds and compositions
    Patent number: 8541600
    Abstract: The invention provides compositions comprising formula 1 steroids, e.g., 16?-bromo-3?-hydroxy-5?-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16?-bromo-3?-hydroxy-5?-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: September 24, 2013
    Assignee: Harbor Therapeutics, Inc.
    Inventor: James M. Frincke
  • Synergistic phytochemical composition for the treatment of obesity
    Patent number: 8541383
    Abstract: Synergistic anti-adipogenic and pro-lipolytic compositions for the prevention and amelioration of adipogenesis and lipolysis mediated diseases, comprising at least two extracts selected from enriched demethylated curcuminoids obtained from Curcuma longa, Moringa oleifera and Murraya koenigii. The anti-adipogenic and pro-lipolytic compositions optionally contain one or more anti-obesic agents. These compositions are useful for preventing anti-inflammatory and free radical mediated diseases.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: September 24, 2013
    Assignee: Laila Nutraceurticals
    Inventors: Ganga Raju Gokaraju, Rama Raju Gokaraju, Trimurtulu Golakoti, Venkateswara Rao Chirravuri, Venkateswarlu Somepalli, Kiran Bhupathiraju
  • Modified nucleotides
    Patent number: 8536323
    Abstract: Modified nucleotides, and methods to modify nucleotides with a moiety or label, such as biotin, that permits their detection and results in a modified nucleotide, and methods of use of the modified nucleotide in quantitative and qualitative assays.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: September 17, 2013
    Assignee: Pierce Biotechnology, Inc.
    Inventors: Kay Opperman, Barbara J. Kaboord, Jean-Samuel Schultz, Christopher L. Etienne, Greg Hermanson
  • Methods for treating inflammatory bowel disease
    Patent number: 8536140
    Abstract: A method is described for treating inflammatory bowel disease in a subject in need thereof. The method comprises administering a formulation comprising at least one ganglioside to the subject, wherein the formulation comprises at least about 50% GD3 by weight of total ganglioside content.
    Type: Grant
    Filed: December 13, 2010
    Date of Patent: September 17, 2013
    Assignee: MTI Meta Tech Inc.
    Inventors: Michael Thomas Clandinin, Eek J. Park
  • Compositions comprising lipoteichoic acid for use in treating pleural effusion or pneumothorax
    Patent number: 8536139
    Abstract: The present invention relates to lipoteichoic acid T for use in treating pleural effusion or pneumothorax. The present invention also relates to the use of lipoteichoic acid T (LTA-T) in the manufacture of a medicament for treating pleural effusion or pneumothorax. The present invention also relates to a kit comprising a pharmaceutical composition comprising lipoteichoic acid T and instructions indicating that the composition is for use as a pleurodesis agent. In addition, the present invention relates to a method of treating pleural effusion or pneumothorax comprising administration of lipoteichoic acid T to a subject.
    Type: Grant
    Filed: September 8, 2008
    Date of Patent: September 17, 2013
    Assignee: ISIS Innovation Limited
    Inventor: Robert John Oriel Davies
  • Method of drug delivery by carbon nanotube-chitosan nanocomplexes
    Patent number: 8536324
    Abstract: Functionalized Single Wall Carbon Nanotube (SWCNT) complexed with nanochitosan for use in the delivery of bioaffecting substances and diagnostic applications. fSWCNT complexed with the chitosan NG042 were used for delivery of DNA-encoding EGFP reporter protein and peptide. The results demonstrate that shown CNT-chitosan hybrid nanoparticles exhibit significantly higher transfection efficiency in vivo than chitosan alone. Furthermore, the functionalized nanotubes were tested for peptide transfer into HEK293 cells. The results showed that the hybrid nanoparticles efficiently transferred peptides. Together, these results show that hybrid SWCNT-chitosan particles increase DNA and peptide transfer into cells.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: September 17, 2013
    Assignee: University of South Florida
    Inventors: Shyam S. Mohapatra, Arun Kumar
  • Steroidal ligands and their use in gene switch modulation
    Patent number: 8536354
    Abstract: The present invention relates to steroidal ligands for use in nuclear receptor-based inducible gene expression systems. The invention further relates to methods of modulating the expression of genes of interest with a system containing one or more nuclear receptor complexes and one or more steroidal ligands. Further aspects include ligand compositions including therapeutic compositions.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: September 17, 2013
    Assignee: Intrexon Corporation
    Inventors: Robert E. Hormann, Silvia Lapenna, Laurence Neil Dinan
  • Sterile hyaluronic acid solutions
    Patent number: 8530641
    Abstract: Sterilized aqueous solution comprising 0.04% to 0.8% by weight hyaluronic acid with a weight average molecular weight from 0.6 MDa to 3.6 MDa, and one or more buffer components selected from the group consisting of boric acid, sodium borate and sodium dihydrogen phosphate. The aqueous solution also has an ionic strength equivalent to an aqueous concentration of sodium chloride from 4% to 18% by weight of sodium chloride and a pH from 6.4 to 7.2. The solution is also filtered through a filter medium that has an average pore size of 0.25 ?m or less to provide a sterilized high salt, hyaluronic acid solution.
    Type: Grant
    Filed: August 1, 2012
    Date of Patent: September 10, 2013
    Assignee: Bausch & Lomb Incorporated
    Inventors: X. Michael Liu, David J. Heiler, Thomas Menzel, Abbie Brongo, Susan E. Burke, Karl Cummins